Clinical pharmacokinetics and pharmacodynamics of colistin
N Grégoire, V Aranzana-Climent, S Magréault… - Clinical …, 2017 - Springer
In this review, we provide an updated summary on colistin pharmacokinetics and
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …
Inhaled antibiotics for gram-negative respiratory infections
E Wenzler, DR Fraidenburg, T Scardina… - Clinical microbiology …, 2016 - Am Soc Microbiol
Gram-negative organisms comprise a large portion of the pathogens responsible for lower
respiratory tract infections, especially those that are nosocomially acquired, and the rate of …
respiratory tract infections, especially those that are nosocomially acquired, and the rate of …
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse …
Objectives This study investigated the exposure–response relationships between unbound
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of …
M Boisson, M Jacobs, N Grégoire, P Gobin… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Colistin is an old antibiotic that has recently gained a considerable renewal of interest for the
treatment of pulmonary infections due to multidrug-resistant Gram-negative bacteria …
treatment of pulmonary infections due to multidrug-resistant Gram-negative bacteria …
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is
key for translation from promising in vitro results to successful clinical implementation …
key for translation from promising in vitro results to successful clinical implementation …
Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models
CB Landersdorfer, J Wang, V Wirth… - Journal of …, 2018 - academic.oup.com
Background The pharmacokinetic/pharmacodynamic (PK/PD) relationship for polymyxin B
against Klebsiella pneumoniae infections is not known. Methods Dose-fractionation studies …
against Klebsiella pneumoniae infections is not known. Methods Dose-fractionation studies …
Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs
Prediction of local exposure following inhalation of a locally acting pulmonary drug is central
to the successful development of novel inhaled medicines, as well as generic equivalents …
to the successful development of novel inhaled medicines, as well as generic equivalents …
Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis
Background Inhaled colistin is becoming increasingly popular against respiratory tract
infections caused by multidrug resistant (MDR) Gram-negative bacteria because it may …
infections caused by multidrug resistant (MDR) Gram-negative bacteria because it may …
Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model
Colistin is often administered by inhalation and/or the parenteral route for the treatment of
respiratory infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa …
respiratory infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa …
Nebulized colistin in ventilator-associated pneumonia and tracheobronchitis: historical background, pharmacokinetics and perspectives
Clinical evidence suggests that nebulized colistimethate sodium (CMS) has benefits for
treating lower respiratory tract infections caused by multidrug-resistant Gram-negative …
treating lower respiratory tract infections caused by multidrug-resistant Gram-negative …